Section 1 of 6
Terms and abbreviations
1 evidence topic · 0 sources
| Abbreviation | Term |
|---|---|
| AAN | American Academy of Neurology |
| AED | Antiepileptic drug |
| AES | American Epilepsy Society |
| AHFS | American Hospital Formulary Service |
| AMPA | Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid |
| ASM | Antiseizure medication |
| AUC | Area under the concentration-time curve |
| AZK | Azetukalner |
| BMI | Body mass index |
| BRV | Brivaracetam |
| CADTH | Canadian Agency for Drugs and Technologies in Health |
| CBZ | Carbamazepine |
| CDC | Centers for Disease Control and Prevention |
| CGI-C | Clinical Global Impression of Change |
| CI | Confidence interval |
| CNB | Cenobamate |
| CNS | Central nervous system |
| CPS | Complex partial seizure |
| CYP | Cytochrome P450 |
| DBP | Double-blind period |
| DBS | Deep brain stimulation |
| DRE | Drug-resistant epilepsy |
| EC50 | Half-maximal effective concentration |
| ED | Emergency department |
| ED50 | Half-maximal effective dose |
| EEC | European Epilepsy Congress |
| EEG | Electroencephalography |
| EMA | European Medicines Agency |
| ESL | Eslicarbazepine acetate |
| FDA | Food and Drug Administration |
| FOS | Focal onset seizure |
| GABA | Gamma-aminobutyric acid |
| GTCS | Generalized tonic-clonic seizure |
| HRQOL | Health-related quality of life |
| HS | Hippocampal sclerosis |
| ICU | Intensive care unit |
| ILAE | International League Against Epilepsy |
| IQR | Interquartile range |
| ITT | Intention to treat |
| KV7 | Voltage-gated potassium channel subfamily 7 |
| LCM | Lacosamide |
| LEV | Levetiracetam |
| LITT | Laser interstitial thermal therapy |
| LTG | Lamotrigine |
| MADRS | Montgomery-Asberg Depression Rating Scale |
| MDD | Major depressive disorder |
| MES | Maximal electroshock seizure |
| MHRA | Medicines and Healthcare products Regulatory Agency |
| mITT | Modified intention to treat |
| MPC | Median percent change |
| MRI | Magnetic resonance imaging |
| mTLE | Mesial temporal lobe epilepsy |
| NADAC | National Average Drug Acquisition Cost |
| NDA | New Drug Application |
| NICE | National Institute for Health and Care Excellence |
| OLE | Open-label extension |
| OR | Odds ratio |
| OXC | Oxcarbazepine |
| PD | Pharmacodynamics |
| PER | Perampanel |
| PGI-C | Patient Global Impression of Change |
| PGTCS | Primary generalized tonic-clonic seizure |
| PGB | Pregabalin |
| PHT | Phenytoin |
| PK | Pharmacokinetics |
| PMDA | Pharmaceuticals and Medical Devices Agency |
| PWE | People with epilepsy |
| QALY | Quality-adjusted life year |
| QOLIE-31 | Quality of Life in Epilepsy Inventory, 31 items |
| RMT | Resting motor threshold |
| RNS | Responsive neurostimulation |
| RR | Risk ratio |
| RR50 | Proportion of participants with at least a 50 percent reduction in seizure frequency |
| SAE | Serious adverse event |
| SMR | Standardized mortality ratio |
| SMU | Seizure monitoring unit |
| SUDEP | Sudden unexpected death in epilepsy |
| SV2A | Synaptic vesicle protein 2A |
| TEAE | Treatment-emergent adverse event |
| TEP | Transcranial magnetic stimulation evoked potential |
| TLE | Temporal lobe epilepsy |
| TMS | Transcranial magnetic stimulation |
| TPM | Topiramate |
| TRAFE | Treatment-resistant adult focal epilepsy |
| US | United States |
| VGB | Vigabatrin |
| VNS | Vagus nerve stimulation |
| VPA | Valproate |
| WAC | Wholesale acquisition cost |
| XEN1101 | Development code for azetukalner |
| ZNS | Zonisamide |